Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ultrasonic Neuromodulation of Cingulate Cortex for Fibromyalgia: A Blinded Randomized Sham-Controlled Trial

NCT07226648 is registered in ClinicalTrials.gov with SPIRE Therapeutics Inc. as lead sponsor.

NCT NCT07226648
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07226648 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ultrasonic Neuromodulation of Cingulate Cortex for Fibromyalgia: A Blinded Randomized Sham-Controlled Trial
Lead sponsor
SPIRE Therapeutics Inc.
Phase
Not applicable
Overall status
Recruiting
Start date
December 11, 2025
Completion date
December 31, 2026
Enrollment
180 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

fibromyalgia